Yes, Ipamorelin can help you lose weight. But, if you are not exercising, and aren’t eating well, it can only do so much. There is no magical supplement which will undo laziness and a horrible diet – keep this in mind. When using it for fat loss, make sure you are exercising. Doing so will naturally increase weight loss results, as you are going to burn more calories, along with the caloric deficit you are already on, for greater results. Further, your diet matters. If you are eating 5000 calories of junk per day, no supplement will help you lose weight – no matter how potent it claims to be!
CJC-1295 is basically a peptide hormone that acts similar to growth hormone releasing hormones (GHRH). Invented by a Canadian biotechnology company called ConjuChem, it is beneficial to athletes because it can bioconjugate with circulating albumin and increase the time it can be used for medical purposes. It achieves this by preventing degradation of its amino acids. With a single dose, it can remain in the body for quite a few days and can cause the growth hormone to be released many times per day. This reduces the frequency of injections needed.
As both CJC1295 and Ipamorelin bind to the pituitary gland and prompt the release of GH, when used together, the production of growth hormone is over 10 times more than when used individually. As it stimulates the body’s natural growth hormone production it also causes the release of IGF-1. The advantages of the CJC peptide is that it helps increases bone density and collagen, as well as boosting the immune system. It will also produce new muscle cells which will be leaner and increases weight loss. The CJC 1295 results are part of years of scientific studies. It primarily increases the production of proteins, which leads to stable bodily functions related to the glands in the body or the endocrine system.
RT-PCR experiments shed light on the molecular mechanisms by which GHRP-6 appeared to modulate the fibrotic response. Among the genes studied (Table 1), GHRP-6 proved to significantly reduce TGFB1 and CTGF () expression, with no effect on PDGFB gene expression. An unexpected finding was that MMP3 appeared significantly reduced in the GHRP-6-treated wounds (). Most meaningfully is that PPARG expression became significantly elevated with GHRP-6 treatment (), as compared to placebo-treated wounds (Figure 7).

Furthermore, the most potent profibrogenic growth factors: Tgfb1, Pdgfb, and Ctgf also appeared significantly underexpressed in the GHRP-6-treated wounds (all ) (Figure 4). In line with this, we observed a significant reduction in the expression levels of Col1a1 and Col3a1 (Figure 4, both ). Concomitantly, we addressed the attention to filamentous and contractile proteins associated with fibroblasts and other differentiated mesenchyme-derived cells. Acta2 appeared close to a significant reduction (), whereas Des, Vim, and Fn transcriptional expression appeared significantly reduced (all ), as compared to placebo-treated wounds.
For example, there are Growth Hormone Releasing Peptides (GHRP’s with names such as ipamorelin and hexarein) which allow for a slow and steady growth hormone release that produces a pulse which mimics natural growth hormone release times and Growth Hormone Releasing Hormones (GHRH’s such as Mod-GRF) for an even stronger natural release of growth hormone and greater presence of growth hormone precursors known as GH “frags” or fragments.
Healthy male Wistar rats (250–270 g) were purchased from the National Center for Animal Breeding (CENPALAB, Havana, Cuba). Animals were individually housed at the animals’ facility of the Center for Genetic Engineering and Biotechnology, Havana, Cuba, and maintained under controlled environmental conditions and light cycles (12/12 hrs). Rats were fed with standard laboratory rodent’s chow under no restriction. Following an acclimation week, the dorsum of the rats was conditioned to receive two controlled full-thickness wounds, under sodium pentobarbital (30 mg/kg) anesthesia. The cuts were generated with disposable 6 mm diameter punch biotomes (Acuderm, Ft. Lauderdale, USA). Two independent experiments were performed using the above described wound model. Thus, 10 rats ( wounds) were used for either GHRP-6 formulation or vehicle (1% CMC) groups in each experiment. Upon wounds induction the rats were randomly assigned to either group. The wounds were cleansed daily with saline, their contours traced on transparent plastic sheets and treated accordingly. Treatments were topically applied twice a day at the same hours during four days. Wounds closure dynamic was measured by planimetric analysis as described previously [16] using the ImageJ software, version 1.46r. Since the GHRP-6 intervention increased the rate of closure, the animals were terminated by anesthesia overdose on day five after wounding. Ulcers and a surrounding margin of intact skin (~5 mm) were collected and hemisectioned. One hemisection was preserved in RNA Later solution for further gene expression studies. The other hemisection was fixed in 10% buffered formalin, paraffin embedded, and 5-μm sectioned. The specimens were stained with hematoxylin/eosin (H/E) and Mallory trichrome to examine collagen deposit. Other slides were destined for immunohistochemistry (as described below).
Hexarelin via CD36 occupation increases the expression of multiple genes involved in fatty acid mobilization in adipocytes toward the mitochondrial oxidative phosphorylation, and many of these upregulated genes are known targets of PPARγ. Consistent with this, electron microscopy of hexarelin-treated adipocytes reflects highly organized cristae formation that spans the entire width of mitochondria, with a concomitant cytochrome c oxidase activity enhancement. Although this signaling and activation cascade has not been described for myocardial cells so far, the potential existence of these phosphorylative and mitochondriogenic mechanisms in the heart, and its potential amplification by GHRP ligands, may eventually contribute to myocardial salvage during critical ischemia periods.47 In a more recent study based on a myocardial infarction model, and addressed to examine whether hexarelin treatment can compensate for ghrelin deficiency in ghrelin-knockout mice, the mortality within two weeks was significantly lower in the hexarelin (6.7%) and ghrelin groups (14.3%) than in the vehicle group (50%). Furthermore, hexarelin was more effective than ghrelin as judged by the ejection fraction and other LV-dependent physiological constants as dP/dt max and dP/dt min, which is a measure of LV global contractility.48
Drug discovery is an uncertain ground in which disappointments and rewards are encountered. Most of those who have been involved in GHRP research have enjoyed clear-cut data, which in most of the cases are all in with very few outs. Exceptionally, a pharmacologically active agent appears to be endowed with such a variety of useful properties as to make it highly drugable. The fact that synthetic GHRPs bind at least two different and biologically significant receptors that seem not to be redundant in nature and are largely represented in most organs and tissues broadens their biological activities and increases their pharmacological potentialities. This suggests that GHRPs may stimulate multiple cells and simultaneously trigger different signaling pathways. The information gathered so far in terms of the molecular cytoprotective mechanism of GHRPs is inconclusive and fragmentary, which has become difficult to disclose the hidden facts behind their biological effects. Nevertheless, it is reasonable that these molecules share the ability to knock life-sensitive pathways and restore critical organelle physiology at very proximal levels. Beyond their ability to enhance the survival of a diversity of cells and tissues before adverse episodes, GHRP members exert an agonistic effect of the GH/IGF-1 axis, promoting anabolia and deterring catabolism and sarcopenia.
Morphological evidences representative of the GHRP-6 effect in a porcine model of myocardial infarction. Effect of the GHRP-6 on AMI size and severity. (A, B) Macroscopic and histological images of AMI damage in animals treated with placebo. (C, D) Macroscopic and histological images representative of the GHRP-6 cardioprotective effect. Histological fragments were in every case collected from apparently normal zones, adjacent to the AMI necrotic core. Rats treated with GHRP-6 exhibited mostly preserved or marginally damaged (sarcoplasmic edema) myofibrils. No myofibrolysis was observed, although a number of ghost nuclei appeared. (H/E, ×20 magnification).
The delegates have decided to accept the advice of the expert advisory committees that the current scheduling of preparations in Schedules 5 and 6 remains appropriate. The delegates noted the decision to retain listing of teeth whitening preparations containing up to 6 per cent hydrogen peroxide or 18 per cent carbamide peroxide in Schedule 5, or exempt when below 3 per cent and 9 per cent respectively, is to some extent also consistent with the evaluation of such products by the European Commission Scientific Committee on Cosmetics and Non Food Products intended for Consumers (SCCNFP).
GHRPs bind to two different receptors (GHS-R1a and CD36), which redundantly or independently exert relevant biological effects. GHRPs’ binding to CD36 activates prosurvival pathways such as PI-3K/AKT1, thus reducing cellular death. Furthermore, GHRPs decrease reactive oxygen species (ROS) spillover, enhance the antioxidant defenses, and reduce inflammation. These cytoprotective abilities have been revealed in cardiac, neuronal, gastrointestinal, and hepatic cells, representing a comprehensive spectrum of protection of parenchymal organs. Antifibrotic effects have been attributed to some of the GHRPs by counteracting fibrogenic cytokines. In addition, GHRP family members have shown a potent myotropic effect by promoting anabolia and inhibiting catabolia. Finally, GHRPs exhibit a broad safety profile in preclinical and clinical settings. Despite these fragmented lines incite to envision multiple pharmacological uses for GHRPs, especially as a myocardial reperfusion damage-attenuating candidate, this family of “drugable” peptides awaits for a definitive clinical niche.
GHRP-6 side effects that are the result of the HGH increases include: flu-like symptoms, joint pain, and carpal tunnel syndrome, headaches, and bloating and water retention. Less likely side effects include: dizziness, tingling or numbness on the skin, reduction of touch sensitivity, nausea, sore bones, and gynecomastia. Although HGH is not a sex hormone, it does serve as an important mediator hormone that works with Estrogen in the development of gynecomastia[1]. This should be kept in mind when utilizing GHRP-6 (or any HGH related compound) with aromatizable anabolic steroids.
Ironically, it only appears that the version of IGF-1 produced in your own muscle has any true anabolic effects. But nonetheless, many folks who’ve used IGF-1 claim to have experienced significant anabolic effects of injections. However, the only evidence for such anabolic effects have been shown in people who are already clinically deficient in IGF-1.
Another benefit of CJC 1295 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS decreases significantly in older adults and also with people who tend to exercise later in the evening. Clinical studies have shown that a once-daily administration of CJC 1295 normalizes the GHRH response and can induce significantly deeper sleep.
Increase in ghrelin – Ghrelin is a hormone that the stomach releases when it is empty. It also helps regulate appetite, promotes fat loss in muscle tissue, and helps in healing damaged tendons. There are studies which also point to a direct link between elevated levels of ghrelin and faster repair of tendons. GHRP-6 causes an increase of ghrelin in the body.

Growth Hormone Releasing Peptide-6 or GHRP-6 is basically a hgH secretagoue, which has the potential to facilitate the effective increase the levels of natural secretion of hgH in our body. At the same time, this compound can also facilitate a sudden increase in body mass and bring about a massive reduction in body fat. GHRP-6 also includes artificial d-amino acids which lead the body to release growth hormones as well. GHRP-6 is not known to work well with GHRH, so it works at the Ghrelin's receptor in place of that receptor.
GH secretagogues differ from exogenous rHGH in their effects primarily because endogenous GH contains all five isoforms of growth hormone, whereas exogenous GH contains only the 20 kilodalton isoform. Different isoforms affect tissues in discreet ways that the 20 kDa isoform cannot. Administration of GH secretagogues causes a pulse-release of GH from the pituitary which is cleared from the body within a few hours. This does not significantly raise plasma insulin-like growth factor 1 (IGF-1) levels.[citation needed]
×